(Q36853538)

16 August 2017

1 reference

title

Duloxetine: a review of its use in the treatment of major depressive disorder (English)

1 reference

16 August 2017

2

Greg L Plosker

1 reference

16 August 2017

James E Frampton

1

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

581-609

1 reference

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721070-00004

The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721070-00004

The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200721070-00004

Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression

21 January 2018

1 reference

12 December 2020

Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor

1 reference

12 December 2020

Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.

1 reference

12 December 2020

Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects

1 reference

12 December 2020

Duloxetine in the long-term treatment of major depressive disorder

1 reference

12 December 2020

Synthesis and biological activity of some known and putative duloxetine metabolites

1 reference

12 December 2020

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

1 reference

12 December 2020

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

12 December 2020

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

1 reference

12 December 2020

Weight gain with antidepressants and lithium

1 reference

12 December 2020

Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies

1 reference

12 December 2020

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

12 December 2020

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants

1 reference

12 December 2020

LY248686, a new inhibitor of serotonin and norepinephrine uptake

1 reference

12 December 2020

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder.

1 reference

12 December 2020

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

12 December 2020

A case of hyponatremia induced by duloxetine

1 reference

12 December 2020

Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats.

1 reference

12 December 2020

Duloxetine in treatment of anxiety symptoms associated with depression

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

12 December 2020

Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects

1 reference

12 December 2020

Antidepressants and sexual dysfunction.

1 reference

12 December 2020

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder

1 reference

12 December 2020

Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features

1 reference

12 December 2020

Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects

1 reference

12 December 2020

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

12 December 2020

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

1 reference

12 December 2020

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

1 reference

12 December 2020

Global burden of depressive disorders in the year 2000

1 reference

12 December 2020

Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study

1 reference

12 December 2020

New hope in the treatment of painful symptoms in depression.

1 reference

12 December 2020

Duloxetine pharmacology: profile of a dual monoamine modulator.

1 reference

12 December 2020

Optimizing antidepressant treatment: efficacy and tolerability.

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

12 December 2020

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

1 reference

12 December 2020

The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition

1 reference

12 December 2020

Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test

1 reference

12 December 2020

The economic burden of depression in the United States: how did it change between 1990 and 2000?

1 reference

12 December 2020

Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study

1 reference

12 December 2020

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

1 reference

12 December 2020

Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder

1 reference

12 December 2020

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine

1 reference

12 December 2020

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

1 reference

12 December 2020

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

1 reference

12 December 2020

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials

1 reference

12 December 2020

The medical management of depression

1 reference

12 December 2020

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics

1 reference

12 December 2020

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

12 December 2020

Management of depression relapse: Re-initiation of duloxetine treatment or dose increase

1 reference

12 December 2020

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

1 reference

12 December 2020

The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

1 reference

12 December 2020

Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range

1 reference

12 December 2020

Meta-analytical studies on new antidepressants.

1 reference

12 December 2020

The burden of disease for treatment-resistant depression

1 reference

12 December 2020

The role of the primary care physician in patients' adherence to antidepressant therapy.

1 reference

12 December 2020

Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis

1 reference

12 December 2020

Assessing full remission.

1 reference

12 December 2020

Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression

1 reference

12 December 2020

Duloxetine and hyponatremia: a report of 5 cases

1 reference

12 December 2020

Effect of age on the pharmacokinetics of duloxetine in women

1 reference

12 December 2020

An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder

1 reference

12 December 2020

Time course of depression-symptom improvement during treatment with duloxetine

1 reference

12 December 2020

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

1 reference

12 December 2020

The effect of antidepressants on lipid homeostasis: a cardiac safety concern?

1 reference

12 December 2020

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

12 December 2020

Anxiety with depression: a treatment need

1 reference

12 December 2020

Epidemiology of depression in primary care

1 reference

12 December 2020

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

1 reference

12 December 2020

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

1 reference

12 December 2020

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

1 reference

12 December 2020

A retrospective pooled analysis of duloxetine safety in 23,983 subjects

1 reference

12 December 2020

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

12 December 2020

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study

1 reference

12 December 2020

Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio

1 reference

12 December 2020

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

1 reference

12 December 2020

Study designs and outcomes in antidepressant clinical trials.

1 reference

12 December 2020

Dual monoamine modulation for improved treatment of major depressive disorder

1 reference

12 December 2020

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

1 reference

12 December 2020

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

1 reference

12 December 2020

Duloxetine: a new selective and dual-acting antidepressant

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation

1 reference

12 December 2020

10.2165/00023210-200721070-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1031590760

0 references

1 reference